Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Ruth L ColemanAlastair M GrayUli C Broedl MdDavid H FitchettJyothis T GeorgeHans J WoerleBernard ZinmanRury R HolmanPublished in: Diabetes, obesity & metabolism (2020)
Empagliflozin-associated changes in conventional CV risk factors in EMPA-REG OUTCOME appear to explain only a small proportion of the CV and all-cause death reductions observed. Alternative risk-reduction mechanisms need to be explored to determine if the observed CV risk changes can be explained by other factors, or possibly by a direct drug-specific effect.